公开(公告)号：US12064482B2

公开(公告)日：2024-08-20

申请号：US17262452

申请日：2019-08-21

申请人： THE UNIVERSITY OF HONG KONG

发明人： Weiping Wang ,  Wen Lyu

IPC分类号： A61K41/00 ,  A61K31/196 ,  A61K47/54 ,  A61K47/69

CPC分类号： A61K41/0042 ,  A61K31/196 ,  A61K47/545 ,  A61K47/6907 ,  A61K47/6921

摘要： The field of various phototriggered drug release and photoreactions, including reactions generally based on triplet-triplet energy transfer with light excitation at long wavelengths. Systems and methods for absorbing energy in a photosensitizer, and methods for making or using such systems, kits including such systems. The systems and methods comprise transferring that energy by triplet-triplet energy transfer to cleave a cleavable or other active moiety, for instance, in order to cause the release of a releasable moiety. In some cases, these may be contained within a suitable carrier material, for example, a particle or a micelle. Such systems and methods may be used in a variety of applications, including various biological or physical applications. For example, such systems and methods may be useful for delivering drugs or other releasable moieties to regions of a subject.

公开(公告)号：US20240294471A1

公开(公告)日：2024-09-05

申请号：US18569361

申请日：2022-07-06

申请人： The University of Hong Kong

发明人： Weiping Wang ,  Yaming Zhang

IPC分类号： C07D207/16 ,  A61K31/4025 ,  A61K45/06 ,  A61P29/00

CPC分类号： C07D207/16 ,  A61K31/4025 ,  A61K45/06 ,  A61P29/00

摘要： ROS-responsive prodrugs and methods of making thereof are disclosed. These prodrugs can contain two captopril moieties and one cinnamaldehyde moiety that are linked by a thioacetal linking moiety; upon cleavage of the thioacetal linking moiety by ROS, the prodrugs can release two captopril or captopril derivatives and one cinnamaldehyde or cinnamaldehyde derivative. Pharmaceutical formulations in a unit dosage form suitable for the delivery of the prodrugs to a subject in need thereof are disclosed. The pharmaceutical formulations may include one or more additional anti-inflammatory active agents in their free form. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating an inflammatory disease or disorder, or treating or ameliorating one or more symptoms associated with an inflammatory disease or disorder in a subject are also disclosed. The inflammatory disease or disorder can be rheumatoid arthritis.

公开(公告)号：US20230020319A1

公开(公告)日：2023-01-19

申请号：US17850720

申请日：2022-06-27

申请人： The University of Hong Kong

发明人： Weiping Wang ,  Tianyi Wang ,  Kaiqi Long

IPC分类号： A61K41/00 ,  A61K31/53 ,  A61K31/4745 ,  A61K31/5377 ,  A61K47/54 ,  A61P35/00

摘要： Compositions and methods for selective mTOR inhibition and/or increase of autophagy in a tissue of a subject have been developed for the treatment of cancer. Caged mTOR inhibitor prodrugs including photo-cleavable protecting groups are provided for selective chemotherapy through an optochemical treatment system. Pharmaceutical compositions of mTOR inhibitors that are deactivated (caged) with a photo-removable protecting group to controllably block the inhibitory activity of the inhibitor are provided. The photo-removable group is cleavable upon exposure to light irradiation, releasing the active inhibitor of mTOR signaling and autophagy at the site of irradiation. An exemplary caged mTOR inhibitor prodrug is a caged OSI-027 prodrug having a DEACM moiety bound thereto (cOSI-027). The cOSI-027 is activated in the region of a tumor by removal of the DEACM protecting group by exposure to light at 420 nm.